Loading
Life sciences · Journal article
BMC Public Health · August 31, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a structured document review that maps 62 seasonal diseases in China to 140 preventive or therapeutic medicines, identifies 41 as requiring priority supply assurance, and proposes policy options for strengthening pharmaceutical supply resilience. The work translates disease epidemiology into operational targets for monitoring and preparedness but does not test the effectiveness of the proposed policy interventions.
Structured document-based review. Seasonal diseases and medicines in China; no patient or provider population enrolled.. Intervention: Document-based risk identification framework linking seasonal disease patterns to medicines requiring priority supply assurance. China.
62 seasonal diseases identified and matched with 140 medicines; 41 medicines required priority supply assurance Infectious and parasitic diseases comprised 51.6% (32/62) of seasonal diseases; respiratory diseases 12.9% (8/62); injury, poisoning and external causes 16.1% (10/62) Monthly disease peaks most concentrated in July and August
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and policy-makers may use this framework to anticipate seasonal medicine supply pressures and plan stockpiling, but the proposed policy interventions (multi-node monitoring, tiered reserves, cross-regional allocation, flexible production) have not been tested for effectiveness or feasibility.
A structured document review that identifies risks and proposes policy options, but lacks empirical testing of interventions or outcomes data to validate the proposed framework.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and policy-makers may use this framework to anticipate seasonal medicine supply pressures and plan stockpiling, but the proposed policy interventions (multi-node monitoring, tiered reserves, cross-regional allocation, flexible production) have not been tested for effectiveness or feasibility.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Background Climate change and seasonal disease patterns are placing growing pressure on medicine supply assurance. Although China has established policies on risk identification, stockpiling, production capacity adjustment, market supervision, and enterprise compliance, seasonal medicine shortages remain challenging due to fragmented policy implementation and limited coordination across the pharmaceutical supply chain. Objective This study aimed to identify risks of seasonal medicine shortages in China and propose policy options for strengthening pharmaceutical supply resilience. Methods A structured document-based review was conducted using official disease control information, clinical guidelines, expert consensus documents, policy documents, and publicly available reports on medicine supply problems. A stepwise selection approach was used. First, seasonal diseases were identified according to epidemiological characteristics and peak occurrence periods. Second, these diseases were matched with preventive or therapeutic medicines based on clinical guidelines, expert consensus statements, or official treatment recommendations. Third, medicines requiring priority supply assurance were further screened based on publicly reported previous supply problems. Results A total of 62 seasonal diseases were identified and matched with 140 medicines used for their prevention or treatment; 41 medicines were further identified as requiring priority supply assurance. Infectious and parasitic diseases were the largest group (32/62, 51.6%), followed by injury, poisoning and other external causes (10/62, 16.1%) and respiratory diseases (8/62, 12.9%). Monthly disease peaks were most concentrated in July and August. Among the 140 matched medicines, chemical drugs and biological products predominated (135/140, 96.4%), and antimicrobial drugs were the largest medicine category (42/140, 30.0%). Antimicrobial drugs remained the largest subgroup (13/41, 31.7%). Production-related supply disruption was the most frequent shortage-risk mechanism (23/41, 56.1%), followed by demand surge and active pharmaceutical ingredient (API) supply disruption (14/41 each, 34.1%). Conclusions This study provides an operational pathway for linking seasonal disease patterns, corresponding medicines, peak-demand periods, and previously reported supply problems. This pathway translates the broad policy goal of seasonal medicine supply assurance into specific targets for monitoring and preparedness, including priority diseases, core medicine categories, peak-demand periods, and medicines requiring closer attention. Multi-node monitoring, tiered reserve management, cross-regional allocation, flexible production capacity, policy coordination, and risk communication may strengthen pharmaceutical supply resilience.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.